These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38561118)

  • 21. Doxorubicin-Loaded Microalgal Delivery System for Combined Chemotherapy and Enhanced Photodynamic Therapy of Osteosarcoma.
    An X; Zhong D; Wu W; Wang R; Yang L; Jiang Q; Zhou M; Xu X
    ACS Appl Mater Interfaces; 2024 Feb; 16(6):6868-6878. PubMed ID: 38294964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.
    Wang J; Hu C; Wang J; Shen Y; Bao Q; He F; Wang H; Gong L; Liu Z; Hu F; Liang J; Zhou Q; Wei L; Wen J; Zhang W
    J Immunother; 2019; 42(9):321-330. PubMed ID: 31219973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo.
    Priwitaningrum DL; Jentsch J; Bansal R; Rahimian S; Storm G; Hennink WE; Prakash J
    Int J Pharm; 2020 Jul; 585():119535. PubMed ID: 32534162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
    Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
    J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zeolitic Imidazolate Framework (ZIF-8) Decorated Iron Oxide Nanoparticles Loaded Doxorubicin Hydrochloride for Osteosarcoma Treatment - in vitro and in vivo Preclinical Studies.
    Wu W; Yu X; Sun J; Han Y; Ma Y; Zhang G; Ma Q; Li Q; Xiang H
    Int J Nanomedicine; 2023; 18():7985-7999. PubMed ID: 38164268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thermosensitive magnetic liposomes with doxorubicin cell-penetrating peptides conjugate for enhanced and targeted cancer therapy.
    Lin W; Xie X; Yang Y; Fu X; Liu H; Yang Y; Deng J
    Drug Deliv; 2016 Nov; 23(9):3436-3443. PubMed ID: 27193383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
    Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
    Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
    Shu H; Yuan B; Huang Y; Wang L; He B; Sun Q; Sun L
    J Orthop Surg Res; 2021 Jan; 16(1):85. PubMed ID: 33509236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.
    Wei H; Chen J; Wang S; Fu F; Zhu X; Wu C; Liu Z; Zhong G; Lin J
    Int J Nanomedicine; 2019; 14():8603-8610. PubMed ID: 31802872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
    Wang Z; Liu Z; Wu S
    Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment.
    Yang Z; Yu S; Li D; Gong Y; Zang J; Liu J; Chen X
    Colloids Surf B Biointerfaces; 2018 Dec; 172():387-394. PubMed ID: 30193198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
    Wang J; Hu F; Yu P; Wang J; Liu Z; Bao Q; Zhang W; Wen J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5127-5138. PubMed ID: 36348018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EYA4 reduces chemosensitivity of osteosarcoma to doxorubicin through DNA damage repair.
    Heng W; Wang T; Wei F; Yang F; Chen C; Yu Z; Du M; Qian J; Zhou C
    Biochem Pharmacol; 2024 Aug; 226():116366. PubMed ID: 38876260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 36. Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy.
    Wang F; Pang JD; Huang LL; Wang R; Li D; Sun K; Wang LT; Zhang LM
    Int J Nanomedicine; 2018; 13():857-875. PubMed ID: 29467575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.
    Lin BC; Huang D; Yu CQ; Mou Y; Liu YH; Zhang DW; Shi FJ
    Med Sci Monit; 2016 May; 22():1761-5. PubMed ID: 27222034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin.
    Ren S; Dai Y; Li C; Qiu Z; Wang X; Tian F; Zhou S; Liu Q; Xing H; Lu Y; Chen X; Li N
    Eur J Pharm Sci; 2016 Sep; 92():137-45. PubMed ID: 27388491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition.
    Wang W; Chen D; Zhu K
    J Exp Clin Cancer Res; 2018 Feb; 37(1):37. PubMed ID: 29475441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.